MIM
PGNX

Monashee Investment Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Monashee Investment Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-240,000
Closed -$1.11M – 219
2019
Q1 		$1.11M Buy
+240,000
New +$1.09M 0.26% 91

Other funds holding PGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Monashee Investment Management's PGNX Position: Q2 2019 in Review

Monashee Investment Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2019, closing a stake of 240,000 shares — an estimated $1.11M sold.

Monashee Investment Management first reported a position in PGNX in Q1 2019 and held it in 1 quarter. The position peaked at $1.11M in Q1 2019. 142 funds tracked by Wall St. Rank hold PGNX as of Q2 2019.

  • Monashee Investment Management reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2019 after selling out during the quarter.
  • Monashee Investment Management sold 240,000 Progenics Pharmaceuticals Inc shares in Q2 2019, an estimated $1.11M.
  • Monashee Investment Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2019 and held it in 1 quarter.
  • Monashee Investment Management's Progenics Pharmaceuticals Inc position peaked at $1.11M in Q1 2019.
  • 142 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2019.

Based on Monashee Investment Management's 13F filing for Q2 2019, filed 7 Aug 2019.